Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Visuell geführter TAP-Block bei laparoskopischer TAPP-Hernienreparatur (VIS-TAP-TAPP)

14. November 2026 aktualisiert von: Łukasz Dyśko, University of Warmia and Mazury in Olsztyn

Wirksamkeit von visuell geführtem Transversus-Abdominis-Ebenen-(TAP)-Block bei der Erholung nach laparoskopischer Leistenbruchreparatur (TAPP - Transabdominale präperitoneale)

This prospective, randomized, placebo-controlled clinical study evaluates the effectiveness of a bilateral transversus abdominis plane (TAP) block performed under direct laparoscopic guidance in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique.

Adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland, are randomly assigned to two groups. In the experimental group, a bilateral TAP block is performed after establishing pneumoperitoneum, using 20 mL of 0.25% bupivacaine on each side (40 mL total; 100 mg total). In the control group, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same technique and anatomical sites.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Postoperative assessments include pain intensity measured using the Visual Analogue Scale (VAS), analgesic consumption, the need for rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using the Post-Anesthetic Discharge Scoring System (PADSS), and adverse events.

The study compares postoperative pain and recovery outcomes between patients receiving laparoscopically guided TAP block with bupivacaine and those receiving placebo saline injections.

Studienübersicht

Detaillierte Beschreibung

Postoperative pain remains an important factor limiting early mobilization and recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Multimodal analgesia combines systemic analgesics with additional approaches, including regional anesthesia. A transversus abdominis plane (TAP) block targets nerves supplying the abdominal wall and can be performed under direct laparoscopic guidance during surgery.

This single-center, prospective, randomized, placebo-controlled study evaluates the effect of a laparoscopically guided bilateral TAP block on postoperative pain and recovery after elective TAPP inguinal hernia repair at the University Clinical Hospital in Olsztyn, Poland.

The planned sample size is 116 adult participants, allocated in a 1:1 ratio to two groups of 58 participants each:

Experimental group: After pneumoperitoneum is established and the laparoscope is introduced, a bilateral TAP block is performed under direct laparoscopic guidance before mesh placement. Bupivacaine 0.25% is injected at a volume of 20 mL per side, corresponding to 50 mg per side and 100 mg in total. The injection site is approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic elevation of the transversus abdominis muscle layer, known as the "Doyle's bulge sign."

Placebo control group: Participants undergo the same TAPP repair and receive bilateral injections of 0.9% sodium chloride, 20 mL per side (40 mL total), using the same injection technique and anatomical sites as in the experimental group.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Analgesic administration and the timing of rescue medication are recorded.

Postoperative pain intensity is assessed using the Visual Analogue Scale (VAS; 0-10) at 0, 2, and 6 hours after the end of surgery. Site-specific assessments include the umbilical port site, the working trocar site on the operated side, the working trocar site on the opposite side, the operated groin, and the ipsilateral testicle, where applicable. Additional assessments include time to first mobilization, analgesic consumption, rescue analgesic use, and readiness for discharge using the Post-Anesthetic Discharge Scoring System (PADSS) at 6 hours. Adverse events, including hematoma, swelling, subcutaneous emphysema, and transient lower limb weakness, are recorded during the 6-hour postoperative observation period.

Exclusion criteria include chronic analgesic use, chronic pain syndromes, psychiatric disorders, alcohol or opioid dependence, recurrent hernias, and emergency surgery. All participants provide written informed consent before enrollment.

The primary outcome is postoperative pain intensity at rest measured using the VAS at 2 hours after the end of surgery. Secondary outcomes include pain intensity at 0 and 6 hours, site-specific pain intensity, analgesic consumption during the first 6 hours, the proportion of participants requiring rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using PADSS at 6 hours, and adverse events.

Statistical analyses compare postoperative pain, analgesic requirements, and recovery outcomes between the bupivacaine and placebo groups. The study hypothesis is that a laparoscopically guided bilateral TAP block with bupivacaine reduces postoperative pain and improves early recovery compared with placebo saline injections.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

116

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Warmisko-mazurskie
      • Olsztyn, Warmisko-mazurskie, Polen, 10-041
        • University Clinical Hospital in Olsztyn, Department of General and Oncological Surgery

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18-80 years
  • Elective laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique
  • ASA physical status I-III
  • Ability to provide written informed consent
  • No contraindications to regional anesthesia or local anesthetic administration

Exclusion Criteria:

  • Recurrent or strangulated inguinal hernia
  • Emergency surgery
  • Chronic pain syndromes or preoperative opioid use
  • Known allergy or hypersensitivity to local anesthetics (bupivacaine or similar)
  • Severe hepatic or renal impairment
  • Psychiatric disorders or inability to provide informed consent
  • Conversion to open surgery during the procedure
  • Technical difficulties preventing TAP block administration

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TAP Block Group (Laparoscopic TAP Block with Bupivacaine)

After pneumoperitoneum is established and the laparoscope is introduced, a bilateral Transversus Abdominis Plane (TAP) block is performed under direct laparoscopic vision. Using a needle and syringe, 20 ml of 0.25% bupivacaine is injected on each side, approximately 2 cm below the costal margin in the anterior axillary line. The correct placement of the local anesthetic is confirmed by the visible "Doyle's bulge sign." Patients receive standard general anesthesia and postoperative pain management identical to the control group.

A bilateral transversus abdominis plane (TAP) block is performed under direct laparoscopic guidance after pneumoperitoneum is established and before mesh placement during TAPP inguinal hernia repair. Using a needle and syringe, 20 mL of 0.25% bupivacaine is injected on each side (40 mL total; 100 mg total), approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic "Doyle's bulge sign." This technique allows direct laparoscopic visualization of the injection site.

Andere Namen:
  • TAPP mit TAP-Block
Placebo-Komparator: Control Group (Placebo Saline Injection)

Participants undergo standard laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Instead of bupivacaine, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same visually guided injection technique and anatomical sites as in the experimental group. All patients receive the same standardized general anesthesia protocol and postoperative analgesic regimen as those in the experimental group.

Bilateral injection of 0.9% sodium chloride, 20 mL per side (40 mL total), into the transversus abdominis plane under laparoscopic visual guidance. The placebo is administered at the same anatomical sites and using the same technique as bupivacaine in the experimental group. An operating room nurse prepares a visually identical syringe without disclosing its contents to the operating surgeon.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Postoperative pain intensity at rest (VAS score) at 2 hours after TAPP hernia repair
Zeitfenster: 2 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), at 2 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation. Scores are compared between the bupivacaine TAP block group and the placebo saline injection group.

2 hours after the end of surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Postoperative pain intensity at rest (VAS score) at 0 and 6 hours after surgery
Zeitfenster: 0 and 6 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), immediately after surgery (0 hours) and at 6 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation.

0 and 6 hours after the end of surgery
Time to first mobilization
Zeitfenster: Within 6 hours after the end of surgery

The time (in hours) from the end of surgery to the patient's first ambulation will be recorded.

Within 6 hours after the end of surgery
Postoperative recovery score (PADSS)
Zeitfenster: 6 hours after surgery

Recovery will be assessed using the Post Anesthesia Discharge Scoring System (PADSS), 0-10; higher scores indicate greater readiness for discharge. A score ≥9 will indicate readiness for discharge.

6 hours after surgery
Incidence of postoperative complications
Zeitfenster: Within 6 hours after the end of surgery

Early postoperative complications such as hematoma, swelling, subcutaneous emphysema, or transient lower limb weakness will be recorded.

Within 6 hours after the end of surgery
Participants requiring rescue opioid analgesia
Zeitfenster: First 6 hours after the end of surgery

Proportion of participants receiving rescue oxycodone during the first 6 postoperative hours.

First 6 hours after the end of surgery
Total oxycodone consumption
Zeitfenster: First 6 hours after the end of surgery

Total dose of oxycodone administered to each participant, expressed in milligrams.

First 6 hours after the end of surgery
Total metamizole consumption
Zeitfenster: First 6 hours after the end of surgery

Total dose of metamizole administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Total paracetamol consumption
Zeitfenster: First 6 hours after the end of surgery

Total dose of paracetamol administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Time to first analgesic request
Zeitfenster: First 6 hours after the end of surgery

Time in hours from the end of surgery to the participant's first request for analgesic medication.

First 6 hours after the end of surgery
Site-specific postoperative pain intensity
Zeitfenster: 0, 2, and 6 hours after the end of surgery

Pain intensity is assessed using the VAS (0-10; higher scores indicate worse pain) separately at the umbilical port site, ipsilateral and contralateral working trocar sites, operated groin, and ipsilateral testicle, where applicable.

0, 2, and 6 hours after the end of surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Marek Kowalczyk, PhD, MD, Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Dezember 2025

Primärer Abschluss (Tatsächlich)

31. Oktober 2026

Studienabschluss (Tatsächlich)

31. Oktober 2026

Studienanmeldedaten

Zuerst eingereicht

23. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. November 2025

Zuerst gepostet (Tatsächlich)

4. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be shared because this is a single-center, investigator-initiated academic study involving a limited number of participants. The collected data include sensitive personal and clinical information that cannot be fully anonymized without compromising data integrity. Only aggregated, de-identified results will be published in peer-reviewed journals and conference presentations.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren